Should you buy Sotera Health (SHC)?
Updated
Sotera Health is a high-quality healthcare sterilization business with 123% free cash flow conversion, a Piotroski F-Score of 8/9, and three consecutive earnings beats, but single-supplier dependency on one ethylene oxide source and high leverage at 3.6x debt-to-equity constrain near-term entry.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Ethylene oxide sterilization capacity relies on a single supplier — a high-severity concentration risk — meaning any supply disruption, regulatory action against that supplier, or pricing negotiation failure could halt the company's core operations. Bear case | The company discloses a second ethylene oxide supply agreement within 12 months, reducing concentration risk below single-source dependency. | →Stable |
| CounterEO supply relationships in industrial sterilization are typically long-established with high switching costs on both sides; the existing supplier has equally strong incentives to maintain the relationship. | ||
Free cash flow conversion at 123% of net income and a Piotroski F-Score of 8 out of 9 demonstrate that the business consistently generates more cash than its accounting earnings suggest, reflecting high-quality recurring revenue from healthcare sterilization contracts. Quality breakdown | Free cash flow conversion remains above 100% of net income over the next 12 months as long-term customer contracts continue to generate predictable cash. | →Stable |
| CounterThe Piotroski score partially reflects low capital expenditure relative to depreciation; if the company needs to reinvest significantly in its sterilization facilities, FCF conversion could normalize downward. | ||
The company beat earnings estimates in 3 of its last 4 quarters with an average positive surprise of 11.4%, with beats of 19.1%, 7.1%, and 15.9% in the three most recent quarters, demonstrating consistent operational outperformance. Catalyst breakdown | Earnings beats continue in at least 2 of the next 3 quarters, maintaining the track record of outperformance. | →Stable |
| CounterThe most recent quarter was only an inline result rather than a beat; if this signals a deceleration in outperformance, the beat streak may be peaking. | ||
Ethylene oxide sterilization capacity relies on a single supplier — a high-severity concentration risk — meaning any supply disruption, regulatory action against that supplier, or pricing negotiation failure could halt the company's core operations.
→Stable- Expectation
- The company discloses a second ethylene oxide supply agreement within 12 months, reducing concentration risk below single-source dependency.
CounterEO supply relationships in industrial sterilization are typically long-established with high switching costs on both sides; the existing supplier has equally strong incentives to maintain the relationship.
Free cash flow conversion at 123% of net income and a Piotroski F-Score of 8 out of 9 demonstrate that the business consistently generates more cash than its accounting earnings suggest, reflecting high-quality recurring revenue from healthcare sterilization contracts.
→Stable- Expectation
- Free cash flow conversion remains above 100% of net income over the next 12 months as long-term customer contracts continue to generate predictable cash.
CounterThe Piotroski score partially reflects low capital expenditure relative to depreciation; if the company needs to reinvest significantly in its sterilization facilities, FCF conversion could normalize downward.
The company beat earnings estimates in 3 of its last 4 quarters with an average positive surprise of 11.4%, with beats of 19.1%, 7.1%, and 15.9% in the three most recent quarters, demonstrating consistent operational outperformance.
→Stable- Expectation
- Earnings beats continue in at least 2 of the next 3 quarters, maintaining the track record of outperformance.
CounterThe most recent quarter was only an inline result rather than a beat; if this signals a deceleration in outperformance, the beat streak may be peaking.
▸ Show 1 more pillar▾ Show fewer
Debt-to-equity of 3.6 imposes a maximum leverage penalty on quality ratings and implies that a meaningful portion of equity returns are being generated through financial leverage rather than operational strength — a risk that could accelerate in a higher-rate environment.
→Stable- Expectation
- Debt-to-equity falls below 2.5 over the next 12 months through free cash flow deployment toward debt reduction.
CounterThe analyst price target implies 24% upside and the company generates 123% FCF relative to net income, suggesting the free cash flow capacity to meaningfully reduce debt; the high leverage may be intentional and manageable.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Free cash flow conversion at 123% of net income and a Piotroski F-Score of 8 out of 9 demonstrate that the business consistently generates more cash than its accounting earnings suggest, reflecting high-quality recurring revenue from healthcare sterilization contracts.
Trip ifFree cash flow conversion falls below 80% of net income for 2 consecutive quarters, indicating the high-quality cash generation thesis is deteriorating.
- P2Ethylene oxide sterilization capacity relies on a single supplier — a high-severity concentration risk — meaning any supply disruption, regulatory action against that supplier, or pricing negotiation failure could halt the company's core operations.
Trip ifCompany discloses a supply disruption from the single EO supplier lasting more than 30 days, affecting more than 20% of sterilization capacity.
- P3The company beat earnings estimates in 3 of its last 4 quarters with an average positive surprise of 11.4%, with beats of 19.1%, 7.1%, and 15.9% in the three most recent quarters, demonstrating consistent operational outperformance.
Trip ifEarnings surprise falls below 0% in at least 2 of the next 4 quarters, reversing the consistent beat pattern.
- P4Debt-to-equity of 3.6 imposes a maximum leverage penalty on quality ratings and implies that a meaningful portion of equity returns are being generated through financial leverage rather than operational strength — a risk that could accelerate in a higher-rate environment.
Trip ifDebt-to-equity ratio rises above 4.0, more than 11% above current levels, indicating leverage is increasing rather than being reduced through cash generation.
How the engine reached this verdict
TrendMatrix's engine output for Sotera Health Company (SHC) is STRONG_BUY_WAIT with medium conviction, score 6.1/10 at $17.14. The C-path quality+growth combination cleared its gates — quality 7.8 and growth 7.5 — with 0.18 asymmetric R:R supporting the read.
BUY_NOW requires reward-to-risk at 0.2 vs threshold 1.5 to clear (0.2 → ≥1.5) OR price pulling back to the entry zone of $15.06 with asymmetry crossing 2.5. The verdict flips to HOLD if overall score deteriorates by ~0.7 from sentiment or technical drift.
On the bull side: Strong earnings beat streak (3/4); Positive news sentiment (+0.67); High-quality business. On the bear side: Concentration risk — Supplier: EO single supplier; Analyst target reached - limited upside remaining; Leverage penalty (D/E 3.6): -1.5. Active engine warnings: V8: Target reached (2.5% upside), News modifier capped: WAIT cannot upgrade to NOW via sentiment alone, V9 Gate Failed: ASYMMETRY:0.2<1.5@spot.
The engine's suggested entry zone is $15.06, currently 13.8% above entry. Target $17.59, stop $13.97, asymmetric R:R 1.67. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 0.5% of portfolio at this asymmetry level (high-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates SHC — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸Positive news sentiment (+0.67)
- ▸High-quality business
Bear case
- ▸Concentration risk — Supplier: EO single supplier
- ▸Analyst target reached - limited upside remaining
- ▸Leverage penalty (D/E 3.6): -1.5